key: cord-0718082-930tkucw
authors: Armendariz, I.; Ferrari, P. A.; Fraiman, D.; Martinez, J. M.; Menzella, H. G.; Ponce Dawson, S.
title: Nested pool testing strategy for the reliable identification of individuals infected with SARS-CoV-2
date: 2021-01-04
journal: nan
DOI: 10.1101/2021.01.03.21249170
sha: e0e3f4b4c445c2036794ed7457d56765d91c155c
doc_id: 718082
cord_uid: 930tkucw

The progress of the SARS-CoV-2 pandemic requires the design of cost-effective testing programs at large scale. To this end, pooling multiple samples can provide a solution. Defining a cost-effective strategy requires the establishment of an efficient deconvolution and re-testing procedure that eventually allows the identification of the carrier. Based on Dorfman's algorithm, we developed an adaptive nested strategy for which we have, for a given prevalence, simple analytic expressions of the optimal number of samples in the starting pool, of the number of partitioning steps (stages) in the optimal path, of the pool sizes in each of these stages and of the expected average number of tests needed to identify the infected individuals. In this paper we analyze the strategy in detail focusing on its practical implementation when there are restrictions that prevent the use of the optimum. More specifically, we analyze how to proceed when the infection prevalence is poorly known a priori or when the optimal requires starting with pool sizes that are too large for the reliable detection of an infected sample. The sensitivity of the RT-qPCR assay, the gold standard RNA detection method, is a major concern in the case of SARS-CoV-2: it is estimated that half of the infected individuals give false negative results. Recently, droplet digital PCR (ddPCR) was shown to be 10-100 times more sensitive than RT-qPCR, making this technology suitable for pool testing. ddPCR has the added value of providing the direct quantification of the RNA content at the end of the test. In the paper we show how this feature can be used for verification purposes. The analyses and strategies presented here should be useful to those considering the adoption of a pooling approach for RNA detection, particularly, for the identification of individuals infected with SARS-CoV-2.

The outbreak caused by the novel Coronavirus, SARS-CoV-2, has spread over almost all 2 countries in the world and running diagnostic tests is required for the analysis of 3 symptomatic individuals. Testing is also a powerful tool used in surveillance at sites of 4 previous or potential outbreaks and for environmental monitoring. The early detection 5 of asymptomatic or pre-symptomatic carriers is crucial to mitigate the spread of the 6 infection, since contact tracing and isolation are required to interrupt the chain of 7 transmission. For this, massive testing campaigns are being implemented, which 8 demand the maximum efficiency in the use of the available resources [1] . Mixing 9 (pooling) multiple samples to test them in a single reaction is an option to increase 10 testing capacity reducing costs and time at the same time. 11 Group or pool testing has been extensively studied for two main applications: (i) to 12 identify "defective" units (in the present case, infected individuals) when the prevalence, 13 p, defined as the probability of being defective, is relatively low [2] ; (ii) to estimate p [3] . 14 In the present manuscript we mostly focus on the identification problem. This is the key 15 aspect for the expansion of the testing capacity; accepting that a negative result in a 16 single reaction indicates that all the individuals whose samples are included in the 17 tested pool are not infected. 18 The first proposal of a pooling strategy for this aim was made by Dorfman [4] in 19 1943. In this strategy, pools are formed containing a number, m, of individual samples. 20 One test is run on each pool to detect the presence of a defective or infected sample in 21 it. Assuming that the detection is sensitive enough, the samples in the pools that test 22 negative in this first stage are identified as non-infected. All the samples that belong to 23 pools that test positive are tested individually at a second stage. The identification of 24 the samples that belong to pools that test negative at first is done with only one test. 25 The identification of those that belong to pools that test positive at first requires m + 1 26 tests instead. A large reduction in the number of tests will then be achieved depending 27 on the relative fraction of pools that test positive at the first stage. This scheme is an 28 example of a class of models that are called adaptative or hierarchical or sequential. In 29 this type of models the actions to be taken at any given stage depend on the test results 30 of the previous stages. The two-stage strategy of Dorfman's was subsequently improved 31 by others [5] [6] [7] including more stages to further reduce the number of tests that are RT-qPCR the target can go unidentified if present in small amounts, and that samples 66 frequently contain inhibitors of the PCR reaction [23] . Moreover, diagnostic sensitivity 67 in symptomatic patients was reported to be in the range of 60%-90% [24] . Thus, for 68 samples with low viral loads, the pooling associated dilution will further reduce the 69 detection of infected individuals to unacceptable levels. The risk of increasing the 70 number of false negative results has raised concerns and delayed the approval of group 71 testing protocols, limiting pool sizes to single digit numbers. This has reduced the 72 impact of pooling strategies and, consequently, the expansion of the world testing 73 capacity. 74 like Next Generation Sequencing were reported to be equally-effective as ddPCR at 84 improving the limit of the detection of SARS-CoV-2 nucleic acid [28] . The 85 implementation of new technologies like ddPCR would remove therefore the major 86 barrier for the adoption of group testing strategies. This might in turn dramatically 87 improve the current world testing capacity soon, raising the need to rapidly obtain 88 efficient algorithms for pool testing [29] . Here we develop the adaptive nested strategy 89 introduced in [14] to address the issues that may arise in practical implementations to 90 detect the presence of SARS-CoV-2 RNA. 91 The strategy introduced in [14] has simple analytic expressions for the optimal 92 number of stages and pool sizes and for the expected number of tests that will allow the 93 identification of the infected individuals in a population as functions of the infection 94 probability, p. In the present paper we analyze how to proceed when p is not known a 95 priori or when there are constraints that prevent the optimal strategy from being used. 96 The analytic nature of the results allows these issues to be handled easily, particularly, 97 to find the optimal strategy when there is an upper bound on the number of samples 98 that can be mixed in a pool. As shown in the paper, the strategy can also be easily 99 implemented in parallel and, thanks to the analytic expressions, the expected number of 100 tests per stage can be estimated a priori which allows the experimenter to make an 101 informed decision on the best way to proceed given the limitations of their set-up. The 102 nested nature of the strategy, on the other hand, allows for result verification when 103 using a type of test that gives a direct quantification of the detected RNA content, such 104 as ddPCR. Regarding cost reduction, for small enough p, the expected number of tests 105 per individual of our optimal strategy is ∼ 3p log(1/p)/ log(3) ≈ 2.7p log(1/p), which is 106 similar to that of the three dimensional array testing studied in [18] and slightly larger 107 than that of the mixed strategy of [13] , ∼ p log(1/p)/ log 2 (2) ≈ 2.1p log(1/p) or of the 108 binary splitting one, ∼ p log(1/p)/ log(2) ≈ 1.4p log(1/p). The cost reduction of the 109 latter, however, is achieved at the expense of having an unknown number of stages, , 110 which is impractical for clinical laboratories due to the pressure imposed by fixed 111 delivery time frames. The order of magnitude of the reduction for small p is mainly 112 determined, in all three cases, by the p log(1/p) factor, which is the same for all. The 113 simplicity of our strategy and the advantages of its nested nature make it a very 114 valuable option to faithfully detect viral RNA saving costs at the same time. We think 115 it can be very useful to minimize the variable costs of SARS-CoV-2-carrier detection 116 and optimize the use of resources in testing facilities. An interface for interested users of 117 the method will be made available shortly at https://wp.df.uba.ar/pooling. 118 

Nested pooling method: description and main formulas. 120 We briefly describe hereby the strategy that we analyze in the present paper quoting 121 the formulas that we will use. More details are provided in S1 Appendix, Sec. 1. The 122 strategy, introduced in [14] , consists in iterating Dorfman's [4] to more than two stages 123 using nested pools. This means that the pools of each stage are obtained as a partition 124 of the pools that tested positive at the previous one. All the pools of a given stage 125 contain the same number of samples. For the definition and optimization of the strategy 126 we work under the assumption that if there is at least one infected sample in a pool the 127 test detects its presence. We also assume that the test does not give "false" detections 128 of infected samples. We discuss in the Results Section how to consider the existence of 129 possible false negatives in pool testing. The strategy is characterized by the number of stages, (k + 1), and the sequence of 131 pool sizes, m = (m 1 , ..., m k ), where m 1 > · · · > m k > 1 and m j is a multiple of m j+1 132 for all j. At the first stage, pools with m 1 samples are tested. Those that test positive 133 are split into pools of size m 2 and are tested at a second stage. The procedure is 134 repeated until the k + 1-th stage. At this last stage all the samples contained in pools 135 that tested positive at the k-th stage are individually tested, i.e., m k+1 = 1. We 136 illustrate the strategy with k = 2 and m = (9, 3) in Fig. 1 . Schematic depiction of the nested pool testing strategy. In the figure the strategy with k = 2 and m = (9, 3) is illustrated when applied to one pool labeled, W 0 . The circles represent individual samples and the rectangles around the colored ones represent pools. The red circles correspond to infected samples. The circles corresponding to the non-infected ones are either green (when they belong to a pool that is being tested at the corresponding stage) or grey (when they have been identified as non-infected at a previous stage). At the first stage all 9 samples belong to the same pool, W 0 , and are tested together. Given that there is an infected sample in W 0 , the test identifies the pool as infected. Thus, W 0 is divided into 3 sub-pools, W 00 , W 01 , W 02 , of 3 samples each that are tested at the second stage. After these tests, W 00 and W 01 , are identified as not infected so that the samples in them are not tested at the third stage. W 02 , on the other hand, is identified as infected and all its samples are tested individually at the last stage. As discussed in the main text and in S1 Appendix, Sec. 1, a label, W i1...ij , can be assigned a priori to the individual samples and the pools of all stages, regardless of whether they are going to be tested as such or not. As illustrated in the figure, it is characterized by a sequence of as many subscripts, i 1 , ..., i j , as stage number with, i 1 , the subscript that identifies the initial pool (in the figure, i 1 = 0).

Given the infection probability, p, the optimal strategy is characterized by the values, k and m, that minimize the cost, D k (m, p), defined as the expected number of tests per individual, ET k /m 1 . The optimal value of k increases with decreasing p. Thus, it only makes sense to use our pooling strategy if [14] :

which is the equivalent of the upper bound of Dorfman's for integer-sized pools. As described in S1 Appendix, Sec. 1, we obtained [14] analytic expressions for the expected number of tests per initial pool at each stage, j:

for the expected total number, ET k = 1 + k+1 j=2 ET (j) k , and for the cost of the strategy:

where q = 1 − p is the probability that an individual is not infected.

Among the universe of nested strategies, those with m = (µ k , . . . , µ) and µ an integer larger than one are of special interest. In particular, we proved in [14] that, for most values of p, the optimal nested strategy is of this form with µ = 3 (see S1 Appendix, Sec. 1). For this reason in this paper we mainly focus on strategies with m = (3 k , . . . , 3). Restricting the analysis to strategies with m = (µ k , . . . , µ), µ > 1, we proved in [14] that the k that optimizes the cost, D k (m, p), is k = k µ (p) with:

where ζ is the largest integer, n ζ , such that n ζ ≤ ζ. We further proved in [14] that 139 setting k = k 3 (p), with k 3 (p) given by Eq. (4) and µ = 3, the cost, D k3 (3 k3 , . . . , 3), p , 140 is of the same order of magnitude, O p log(1/p) , as the cost of the optimal strategy for 141 that p. Thus, a strategy with m = (3 k , 3 k−1 , . . . , 3) and k = k 3 (p) will provide good 142 results (i.e., an expected number of tests per individual of the same order of magnitude 143 as the one of the optimal nested strategy) for any p < 1 − 1/3 1/3 .

We also found in [14] that when m = (µ k , . . . , µ) the standard deviation of the number of tests per individual can be written as:

Nested pooling method: stochastic numerical simulations previously explained: given a stage, j, and a pool with m j samples, only the pools that 158 contain a 1 in their sequence are tested at stage, j + 1, for which they are subdivided 159 into m j /m j+1 pools of m j+1 samples each. As in the case of the first stage, the samples 160 in each subpool that is tested at the j + 1 stage are chosen sequentially along the 161 sequence that characterizes the pool of the j-th stage from which they derive. This way 162 of organizing the simulation uses the labeling of pools and samples that is illustrated in 163 Fig. 1 and described in detail in S1 Appendix, Sec. 1. In brief, if we order the initial 164 individual samples in a row, as done in Fig. 1 , and define a priori the pools of the j-th 165

December 31, 2020 6/28 stage as the sets containing m j subsequent samples along this row (the rectangles in 166 Fig. 1 ), we associate (k + 1) subscripts, i 1 i 2 ...i k+1 , to each individual sample that serve 167 to uniquely identify the pools each of them belongs to at any given stage. This is 168 apparent in Fig. 1 where the individual samples are represented along a horizontal line 169 with the first one starting from the left being labeled by the subscripts 000 and the last 170 one by 022. In this case we are considering only one initial pool, W 0 , and that is why 171 the first subscript of each individual sample is i 1 = 0. If the number of first stage pools 172 (of size m 1 ) is N w , then 0 ≤ i 1 ≤ N w − 1 and 0 ≤ i j ≤ m j−1 /m j for 2 ≤ j ≤ k. Let us 173 describe for simplicity the case in which m j−1 /m j = 3. Let us consider an individual 174 sample with subscripts, i 1 ...i k+1 . Then, i 1 gives the order along the row (starting from 175 0) of the first stage pool that the sample belongs to. The order of the second stage pool 176 it belongs to is 3i 1 + i 2 , that of the third one is 3 2 i 1 + 3i 2 + i 3 , and so on. In particular, 177 the position along the row (starting from 0) of the individual sample with subscripts is 178 i k+1 + 3i k + ... + 3 k−1 i 2 + 3 k i 1 . This labeling is also illustrated in Fig. 1 of S1 179 Appendix, Sec. 1. determined by the number of stages, k. For each p, the value, k, that characterizes such 192 optimal strategy is given by the function, k 3 (p), (Eq. (4) with µ = 3). k 3 (p) is a 193 staircase function of p that increases with decreasing p as shown in Fig. 2 (a). 194 We show in Fig. 2 (b) the expected number of tests per individual, D k (black, Eq. 3), 195 and the standard deviation of this number σ(m, p) (red, Eq. (5)) for strategies with 196 m = (3 k , . . . , 3) and k = k 3 (p), the optimal number of stages depicted in Fig. 2 (a) . The 197 fact that D k ∼ σ(m, p) could be worrisome, but is not. If the strategy is applied several 198 times, the average number of tests per individual will approach the expected value, derived for some of the cases as explained in S1 Appendix, Sec. 1, are also shown with 218 green bars. 219 We observe in Fig. 3 (a) that approximately 58% (theoretical value (1 − 0.0201) 27 ) of the 27-sample pools require only one test, i.e., contain no infected samples. It implies that 15,660 individuals are expected to be reported as negative using only 580 tests. This is the main reason for the large reduction in the average number of tests per individual (∼ 0.2, instead of 1) that need to be performed in this example. This becomes apparent if we contrast the histogram of Fig. 3 (a) with the average number of tests per pool, ∼ 5.4. The second most frequent situation in Fig. 3 (a) (with ∼ 34% of the instances) is that in which the number of tests performed per pool is 10. This corresponds to initial pools with only one infected sample or to the few ones with more than one infected sample that remain in the same pool until the k-th stage (see S1 Appendix, Sec. 1). In such a case, at any given stage, only one pool "makes it" to the following stage. Thus, the total number of tests that have to be performed for each of these pools is:T

December 31, 2020 8/28

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 4, 2021. ; Green bars correspond to the theoretical values that we computed (see S1 Appendix, Sec. 1). The apparent mismatch between theory and simulations is solely due to fluctuations and disappears as the number of initial pools is increased. and the number of tests per individual can be written as:

withp = 1/m 1 . The latter is equal to the expected number of tests per individual for 220 realizations with at most one infected sample per initial pool if we setp equal to the 221 infection prevalence, p. It also coincides with the linearization of Eq. (3) replacing,p, by 222 the infection probability, p (see S1 Appendix, Sec. 1). We proved [14] that the cost of 223 the optimal nested strategy is smaller than the one given by Eq. (7). This is reflected in 224 the example of Fig. 3 (a). shows that, as p decreases within the range 235 for which k 3 = 3 is optimal, the fraction of initial pools that require the largest number 236 of tests decreases as well while the fraction of those that require only one test (i.e., no 237 infected samples), grows. The increasing ratio, σ/D 3 , can then be related to an 238 increasing fraction of instances with no infected samples that are resolved with only one 239 test. The reason why σ stays relatively "large" as this happens is easy to understand if 240 we assume that the initial pools can only have 0 or 1 infected sample. In such a case, . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint us call,p, the probability that X = 1. The mean and standard deviations of X are 245 X =p andσ = p(1 −p) and satisfyσ/ X > 1 forp < 1/2 withσ/ X increasing 246 for decreasingp < 1/2. Thus, the ratio increases because the deviation approaches zero 247 more slowly than the mean. This translates into a similar behavior for the number of 248 tests for which the mean and standard deviations are, respectively, 1 +p(T k − 1) and

. From the point of view of the number of tests it means that the 250 "worst" pools (those with exactly one infected sample) are solved with a number of tests 251 given by Eq. (6) which is clearly smaller than the number of samples in the initial pool, 252 µ k , for µ = 3 and k ≥ 2. The optimal strategy of the form (µ k , . . . , µ) for a given p is such that pµ k < 1.

Thus, initial pools with more than 1 infected sample have a (pool) fraction of infected 255 samples larger than p. In such a case, the best case scenario is the one where the In this Section we present a series of analyses to determine the best nested strategy 273 when the use of the optimal one described so far is prevented by constraints or when the 274 December 31, 2020 10/28

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ;  strategy is applied in parallel on a given number of pools at the same time. Namely, two 275 problems that we may encounter in a practical implementation of the nested pool 276 strategy is uncertainty in the estimate of p and an incompatibility between the optimal 277 pool sizes and the largest number of samples that can be pooled to obtain reliable 278 results. Even though p can be estimated when the strategy is applied allowing and the 279 strategy can be retuned (see S1 Appendix, Sec. 2), in this Section we study the cost 280 reduction that is obtained when using our nested strategy outside its region of 281 optimality. Next we provide a solution for cases in which the maximum number of 282 samples that can be pooled is below the first stage pool size, m 1 , of the optimal nested 283 strategy for the given p. Finally, the performance of the nested pool strategy is 284 analyzed when the test is run in parallel on several pools at the same time. We 285 compare, in particular, the expected number of pools to be tested at any given stage 286 with those tested at the first one.

Pooling tests under unknown prevalence. 288 We analyze in this subsection how much of a reduction in the number of tests is approximately half an order of magnitude. It is likely that the order of magnitude of p 294 be known a priori. As it is apparent in Fig. 2 , it is p 3,k and p 3,k+2 that differ by 295 approximately an order of magnitude. In fact, it can be deduced from Eq. (4) that

Thus, we will compare the use of a 297 strategy with (3 k , . . . , 3) for a situation with p ∈ (p 3,k+2 , p 3,k+1 ) and of another with 298 (3 k+1 , . . . , 3) for a situation with p ∈ (p 3,k+1 , p 3,k ). The first analysis will also shed light 299 on how to handle cases in which the optimal m 1 exceeds the maximum pool size allowed 300 for the tests to give reliable results. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint not optimal, the (k + 1)-th stage strategy will produce a noticeable reduction in the 307 number of tests per individual for p < p 3,k+1 . In fact, the discussion on Fig. 3 showed 308 that when a strategy of the form m = (3 k , . . . , 3) is applied to situations with p smaller 309 than the smallest value for which the strategy is optimal (i.e., p < p 3,k+1 ), initial pools 310 with more than one infected sample become increasingly rare. In fact, if p is small 311 enough the number of infected samples in a finite population will be almost zero. The 312 expected number of tests per individual will be correctly approximated by Eq. (7) and, 313 because of its low value, it will also be smaller than the standard deviation. This is 314 illustrated in Fig. 6 (a) where we show the results of stochastic numerical simulations in 315 which we apply the strategy with m = (3 k , . . . , 3) and k = 3, which is optimal for 0.0218) is obtained compared to that of the suboptimal case. However, in the analyzed 337 example, the suboptimal case still produces a very noticeable reduction in the number 338 of tests. Even when the resulting standard deviation, 0.066, is slightly larger than the 339 expected value, 0.0507, it is clear that practically no pool will require more than 10 tests 340 to be resolved (which is < 40% of the number of samples in the initial pool). In general, 341 if we apply the m = (µ k , . . . , µ) strategy to a situation with p p µ,k+1 , not only the 342 expected number of tests per individual, (1 + kµ)/µ k , will be given by Eq. (7), but more 343 likely the number of tests per pool required will never exceed (1 + kµ), which is smaller 344 than the number of individuals tested per initial pool, m 1 = µ k for k ≥ 2 and µ ≥ 3.

Based on the discussion of this Section we conclude that, if the value of p is poorly 346 known a priori, it is advisable to use a strategy with m = (3 k , . . . , 3) and a relatively 347 small number of stages, (k + 1). As discussed in S1 Appendix, Sec. 2, after the 348 application of the first stage of the strategy to several pools, the estimate of p can be 349 improved and the strategy (i.e., the value of k) be retuned.

Maximum number of samples allowed in a pool. 351 We now analyze what can be done if the optimal strategy requires a value, m 1 , that is 352 larger than the maximum allowed for the test to be reliable. To perform this analysis 353 we arbitraritly set the bound m 1 ≤ 120. We then assume that we are dealing with a 354 situation such that 0.00150588 < p < 0.00451083 for which the optimal strategy of the 355 December 31, 2020 12/28

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We compare in Fig. 5 (b) these 11 strategies that have m 1 = 120 (all in blue but the 371 one with m = (120, 24, 6, 2) in red) with the 5-stage strategy, m = (3 4 , 3 3 , 3 2 , 3) (black), 372 which is optimal, according to the theory, for 0.00451083 < p < 0.0134716. We observe 373 that the m = (3 4 , 3 3 , 3 2 , 3) scheme gives the largest reduction in the number of tests for 374 0.0025 p and that, even if not optimal, it does give a noticeable reduction for smaller 375 values of p. For the smallest values of p, the best among all these strategies is the one 376 with m = (120, 24, 6, 2). As p is reduced beyond the values illustrated in the figure, the 377 cost of all the strategies that start with m 1 = 120 approach the same value, which is . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint proofs of [14] that restrict the space over which the search has to be performed. Starting 390 with m 1 = 3 k , however, has other advantages as discussed in the following. observe that the number of tests expected for the j−th stage increases with j. This 408 means that we can expect the largest number of tests at the last stage, k + 1. The ratio 409 of the number expected for two subsequent stages, however, never exceeds ∼ 2.1 for any, 410 p, smaller than the maximum value for which the strategy is optimal. This is reflected 411 in Fig. 7 (b) where we have plotted the ratio ET Given that ET (j) k (m, p) for m = (µ k , . . . , µ) decreases with p, it is meaningful to compute it for k = k µ at p = p µ,kµ (i.e., at the maximum probability for which the scheme m = (µ kµ , . . . , µ) is optimal). Thus:

which is independent of k. We show in Fig. 7 (b) plots of ET (j, µ) as functions of j (allowing j to take any real number) for various values of µ. We observe that ET (j, µ) approaches a limiting value, ET µ , with increasing j. This limiting value, which puts an upper bound on the number of tests that one can expect to be performed at any stage starting from a pool with m 1 = µ kµ samples using a scheme of the form m = (µ k , . . . , µ) for a population with p ≤ p µ,kµ , is

This implies that, if one uses a scheme of the form m = (3 k3 , . . . , 3) for situations in 421 which the infection probability is p ≤ p 3,k3 then we can expect that the number of tests 422

December 31, 2020 14/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint at each stage will never be above ET 3 ∼ 3.296 times the number of tests of the first 423 stage. The upper bound, ET µ , increases with µ. This means that the largest µ the 424 largest will be the expected number of tests at any given stage compared with the first 425 one (provided that p is smaller than the corresponding p µ,k ). This is an important 426 feature when one wants to run the proposed scheme on several first stage pools in 427 parallel and there is a limit on the number of tests that can be performed 428 simultaneously. At the first stage one would have a number of pools equal to this limit. 429 Thus, a less frequent overflow of tests with respect to the first stage will facilitate the 430 bookkeeping of the method. k (µ kµ , . . . , µ, p k ), as a function of j for µ = 2 (black), µ = 3 (red), µ = 4 (blue) and µ = 5 (magenta). We plotted the curves for any value of j, but it must be noted that only the integer ones are meaningful.

We show in Tables 1 and 2 the results of stochastic numerical simulations performed 432 as before but this time assuming that at most 96 tests can be run simultaneously at any 433 given stage and that at most 32 individual samples can be mixed in any given pool. The 434 upper bound on the number of simultaneous tests comes from one of the typical sizes of 435 commercially available multi-well plates where to run the tests. On the other hand, the 436 maximum number of individual samples that can be mixed to detect the presence of a 437 single one infected with SARS-CoV-2 using RT-qPCR has been estimated to be 32 438 in [30] . Table 1 corresponds to a situation in which the infected population is p = 0.02 439 for which the optimal number of stages for a scheme of the form (3 k , . . . , 3) is 440 k = k 3 = 3. We then compare in this table the results of running the tests in parallel for 441 the (3 3 , 3 2 , 3) scheme and for a scheme that starts with m 1 = 32. We use the same 442 population in both cases, with some added samples in the latter case. While the former 443 scheme is optimal for p = 0.02 and satisfies that m 1 < 32, the latter puts the largest does not improve its performance. Namely, the case with m 2 = 16 and m 3 = 4 does not 450 resolve all cases in two parallel rounds, but needs a third one. This is consistent with 451 the proofs of [14] that we referred to before. We then perform the same comparison for 452 p = 0.008 for which the optimal scheme of the form (3 k , . . . , 3) has k = k 3 = 4. In this 453 December 31, 2020 15/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; case we would have to start with m 1 = 2 4 = 81 samples which is not allowed. Then, we 454 compare the same two schemes as before and a scheme that starts with m 1 = 32 but 455 has k = 4 instead of k = 3. We show the results in Table 2 . There we see that there is 456 no pool overflow in this case, something that we could have expected for the (3 k , . . . , 3) 457 scheme based on the discussion of Fig. 7 . The comparison shows that the (3 k , . . . , 3) 458 scheme is the one that requires the smallest number of tests per individual even if the 459 number of stages is not the optimal for the infection probability of the population. 460 Table 1 . Comparison between the optimal strategy and one that starts with the maximum allowed number of samples in a pool. m 1 = 27, m 2 = 9, m 3 = 3, m 4 = 1. Results of stochastic numerical simulations in which the nested pool strategy is performed simultaneously on up to 96 pools each of which can have at most 32 samples. At the first stage there are exactly 96 pools, but at the second stage the number can be larger. This is what we call "pool overflow" in the table. These unresolved pools can be tested whenever there is room. In the table we put in the same row all the pools of equal size that are available for testing at that point (identifying them with their corresponding value of j). The optimal strategy for p = 0.02 (the one with m 1 = 27) produces less overflow than those that start with the largest allowable number of samples in a pool (m 1 = 32).

Based on the above discussion, we conclude that the schemes with m = (3 k , . . . , 3) 461 are not only good because of the relatively fewer number of tests per individual they 462 require (even for probabilities for which they are not optimal), but also because they 463 produce some of the smallest overflows when running the strategy in parallel. In clinical 464 laboratories the turnaround time directly impacts on the productivity. Thus, even when 465 December 31, 2020 16/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; Table 1 but for a situation with a fraction of infected samples for which the optimal strategy requires that 81 samples be mixed together in the initial pools. In this case, the number of infected samples is low enough so that the average number of initial pools that test positive is very low and there is no "pool overflow". strategies in which the pools are subsequently divided in two subpools produce less 466 overflow, they require more stages and, consequently, more time to identify the infected 467 samples than those in which the pools are subdivided in three.

Taking advantage of the nested strategy for result verification 469 and self-consistency tests.

Any test carries some level of uncertainty. There are two main ways to reduce this 471 uncertainty. One way is to employ novel technologies, to improve the limit of detection 472 and therefore the test sensitivity, and use commercial kits less prone to interference.

The other way is to repeat the test several times. A nested strategy as the one 474 described in this paper has the advantage that a fraction of the samples is retested 475 several times, particularly those that are identified as infected. The quantification of the 476 analyte, on the other hand, could provide self-consistency checks to increase the 477 December 31, 2020 17/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. [23, 25, 31] . ddPCR is an end-point method that quantifies the nucleic acid 482 content (provided that it is within a certain range) without the need of calibration 483 curves [32, 33] (S1 Appendix, Sec. 3 for details).

The increased sensitivity of ddPCR also enhances the reliability of the detection of 485 the reporters that are used in any PCR test to confirm that the reaction has proceeded 486 correclty as well as the integrity of the sample, avoiding false negative results due to 487 inappropriate handling. As an internal control, a human RNA molecule expected to be 488 found in all the samples regardless of the presence of viral RNA is co-amplified. If the 489 control RNA is not detected, it is assumed tnat the sample was inappropriately informed reliably would be those tested at the level of individual samples. In the case of 496 our strategy, this would occur at the very last stage, a stage that is reached by relatively 497 few non-infected samples compared to those contained in pools that do not test positive 498 at previous stages. The fraction of non-infected samples, on the other hand, should be 499 at least two thirds of those analyzed for the application of pool testing to make sense 500 (see Eq. (1)). Not informing most of the non-infected samples means that the strategy 501 would be applied mainly to identify those that are detectably infected. In other words, 502 it could be technically possible that all the samples for which both, no signal of viral 503 RNA is detected and have not been tested individually in the process of pool 504 partitioning, are false negatives. This type of events have been shown to be very 505 unlikely and of having a larger probability of false negatives is currently accepted as a 506 limitation of the pooling method with no significant clinical meaning. Considering these 507 limitations, test pooling may still serve for epidemiological purposes and for continuous 508 validation of the method. As analyzed in this Section, however, accurate quantification 509 that ddPCR provides can be of help to enlarge the truly confirmed set of negative tests. 510 We discuss in what follows how a self-consistency check could be applied to the 511 results obtained with our strategy when the nucleic acid content is quantified as 512 described in S1 Appendix, Sec. 3, and how this quantification can be used to detect 513 some of the flawed pooled samples that test negative. We also use the ddPCR 514 quantification to determine the probability of detecting a single infected sample in a 515 pool as a function of the pool size and the viral load.

In ddPCR the volume that goes in the reaction tube is subdivided into many (20,000) sub-volumes. At the end, the test gives (ideally) the number of sub-volumes that contained, at the beginning of the test, at least one molecule of the nucleic acid of interest (RNA in our case). As explained in S1 Appendix, Sec. 3, if the fraction of occupied sub-volumes is bounded away from 0 or 1, a range of possible values for the concentration of the RNA detected by the test can be obtained. As derived in S1 Appendix, Sec. 3, when testing a pool of m j samples, the RNA concentration that is December 31, 2020 18/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint estimated at the end of the ddPCR corresponds to: R /D 7.410 6 /ml (see S1 Appendix, Sec. 3, where we also 528 discuss how this range could eventually be enlarged). 529 We discuss now how the nested nature of the strategy can be used for test verification. Let us then consider an m j -sample pool, m j > 1, that tests positive at the j-th stage so that, at stage j + 1, is sub-divided into m j /m j+1 sub-pools with m j+1 samples in a sample (test) volume, V s (V t ), each. In view of Eq. (10), the expected number of RNA molecules added over all the (m j /m j+1 ) m j+1 -sample sub-pools of the m j -sample pool is:

where c (j+1) R;

is the RNA concentration, before dilution, that is estimated for the -th sub-pool at the end of the ddPCR test of the j + 1-th stage (see S1 Appendix, Sec 3 for more details). Eqs. (10) and (11) imply that:

which is a condition that the RNA concentrations derived from the ddPCR tests 530 performed on the same subset of samples at two subsequent stages should satisfy. As 531 explained in S1 Appendix, Sec. 3, the ddPCR quantification gives an interval of possible 532 values for the corresponding concentration, c R . The uncertainty, however, can be 533 relatively low compared with the expected value, especially away from the lowest end of 534 concentrations for which the quantification is possible (see Fig. 3 in S1 Appendix). In 535 the case of low viral load, the RNA content could be very small, especially for large 536 pools. In the case of the human RNA it is possible that the upper bound be reached.

This can be avoided by choosing judiciously the piece of human RNA to be detected.

Depending on the infection, the upper bound might also be reached for the viral RNA 539 concentration in the case of individual samples. In the case of individuals infected with 540 SARS-CoV-2, for example, the viral RNA detected could be larger than 10 7 541 copies/ml [34, 35] in throat samples (even in the testing volume) and reach ∼ 10 11 542 copies/ml in sputum [36] . In any case, the comparison of the RNA concentrations 543 derived in two subsequent stages, either viral and/or human, can be used to verify that 544 both stages have proceeded as expected. The advantage of the nested strategy is that 545 the set of samples that would require some re-testing, if an inconsistency is found, is 546 December 31, 2020 19/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint reduced with respect to strategies that are either non-adaptive or that mix up the 547 samples at random at every stage.

Knowing the "genealogy" of the infected samples, i.e., the pools they belonged to at 549 any given stage, is also of help for the quantification of the viral RNA content when its 550 concentration in the infected individual sample is too high. Namely, if at the last stage 551 this concentration exceeds the upper bound allowed for a reliable quantification (see S1 552 Appendix, Sec. 3), then, in certain cases it is possible to deduce it from the 553 concentration determined at a previous stage.

Let us consider the example of Fig. 1 , which corresponds to a pool, W 0 , with 9 samples at the initial stage, only one of which is infected. The infected sample, W 020 , is identified at the very last stage. Let us use the same labeling that we use for pools and samples to identify the RNA concentrations in each of them and let us assume thatc 020 is large enough so thatc R;020 /D exceeds the upper bound for a reliable quantification with ddPCR (∼ 7.4 10 6 ml −1 , see S1 Appendix, Sec. 3). Knowing the genealogy allows us to infer that this is the only infected sample in the second-stage pool, W 02 and in the first-stage one, W 0 . In either of these two cases the RNA concentration is diluted with respect to the last stage (by factors 3 and 9, respectively). Therefore, it is possible that the RNA viral concentration in W 02 or in W 0 could be quantified. Since we know that it is only due to the (020) sample, we can then infer,c R;020 . Namely, the application of Eq. (10) to the pools that contain the (020) sample at stages j = 1 and j = 2 implies that c (1)

Clearly,c R;020 can be estimated using either Eq. (13) or (14), depending on whether (0122), that remain in the same pool at stage j = 2, in 560 particular, their viral load could be estimated provided that the RNA content of one of 561 them could be quantified at stage j = 3.

Minimum viral load detectability and maximum pool size using ddPCR 563 One of the main limitations of test pooling within the problem addressed in this paper is the loss of sensitivity due to the dilution of the samples in the pool. In that regard, the worst case scenario is that in which all the samples but one correspond to healthy individuals. Let us consider an m j -sample pool in which the i-th sample corresponds to an infected individual whose viral RNA concentration isc R;i (defined as in Eq. (10)).

Assuming that ddPCR allows the detection of up to a single RNA molecule in the testing volume, we compute the probability of having at least one viral RNA molecule in the pool, P (N (j) R ≥ 1), as a function ofc R;i as (S1 Appendix, Sec. 4):

December 31, 2020 20/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint individual samples reported in [34] : the curve in blue corresponds to the minimal load 568 detected (11.1 copies/test) and the one in purple to the average minus SEM (651-501 569 copies/test) detected in samples of nasal swabs (the specimens with lowest viral content 570 reported in [34] ). There we observe that a single sample with the minimal viral load 571 detected in [34] could be detected, according to our calculation, in > 97% of the cases in 572 3-sample pools and in > 70% of the cases in 9-sample ones. The lowest end of the 573 average obtained in nasal swabs, on the other hand, could be detected with 3, 9 or 574 27-sample pools in over 99% of the cases. Considering that the average viral loads 575 detected in throat swabs and sputum samples were, respectively, ∼ 4 and 27 times the 576 average in nasal swabs, it seems that a single infected sample would be detected in a 577 fairly large fraction of cases using pools of 27 or more samples of these specimens.

Detecting flawed pooled samples 579 The aim of this analysis is to determine whether it is possible to identify "flawed" samples in pools that test negative. Here by "flawed" we mean samples with undetectable levels of the human RNA that should be present in any sample. Assuming that there is not a huge variability of its concentration among individuals we can expect that pools of all stages should be characterized approximately by the same concentration, c R = c (j) R , 1 ≤ j ≤ k + 1, if the original samples are not flawed and the PCR tests proceed correctly. Now, not only the quantification with ddPCR has an uncertainty but also the human RNA content varies between individuals. The question is how the variability in the values, c R , that may be derived with ddPCR compare with the change that one flawed sample in a pool would induce in c R . To analyze this situation, we introduce the notation

December 31, 2020 21/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ;  to denote the mean number of human RNA molecules of the i-th individual in a volume 580 of size, V s . Let us then consider an m-sample pool in which each individual sample 581 occupies a volume, V s /m, of the sample volume, V s . In such a case the i-th individual 582 contributes with a number of human RNA molecules of mean λ i /m. Including the 583 human to human variability implies that the values, λ i , are (independent) instances of a 584 random variable with a certain distribution (if none of the individual samples are 585 flawed). This is a distribution at the level of the human population that, for simplicity, 586 we consider it is Normal of mean, λ, and standard deviation, σ (see S1 Appendix, 587 Sec. 5). We then consider that an m-sample pool in which none of the samples is flawed 588 is characterized by a sequence, λ 1 , λ 2 , . . . , λ m of independent identically (Normal) 589 distributed (i.i.d.) random variables. If there is one flawed sample in the pool, then, the 590 corresponding λ i will be zero and the other m − 1 will be i.i.d. random variables. 591 We now consider a ddPCR experiment in which the testing volume is divided into M sub-volumes. Proceeding as explained in S1 Appendix, Sec. 5, we compute the likelihood that x of the M sub-volumes come out as not having any RNA molecules at the end of the test under the two situations that we want to distinguish: (i) all the individual samples were "good", i.e., they all contributed with human RNA molecules to the original sample volume, V s ; (ii) one of the samples was "flawed", i.e. did not contribute any human RNA to this volume. We obtain:

Therefore, the accuracy of the test (the fraction of instances for which the classification is correct) can be written as:

where Φ(z) = is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint Using V t = 20µl (a typical testing volume) we obtain that the concentrations in the 608 orginal sample, c R , must satisfy 8.6 10 3 /ml < c R /D < 1.48 10 7 /ml for m = 3 and 609 8.5 10 4 /ml < c R /D < 6.8 10 6 /ml for m = 9. The range in the m = 9 case is fully 610 contained within the range for which ddPCR can provide an accurate estimation of the 611 RNA concentration (see S1 Appendix, Sec. 3). The highest end for the m = 3 case goes 612 beyond the limit set by ddPCR; their overlap occurs for: 613 8.6 10 3 /ml < c R /D < 7.4 10 6 /ml. Assessing whether these conditions can be satisfied in 614 actual situations requires further studies. In case that this discrimination could be 615 possible for two successive stages, a re-checking along the lines already discussed for the 616 viral RNA could be performed. On the other hand, knowing the genealogy of the pools 617 that test positive at the k-th stage (the ones containing the samples that are tested 618 individually at the last stage), we can go backwards and identify sets of negative pools 619 that might contain missing samples. This would give a further validation on top of what 620 could be determined at the time that the corresponding pools test negative.

In this paper we have analyzed in detail the adaptive nested strategy for test pooling 623 introduced in [14] which is an extension of Dorfman's algorithm for more than two 624 stages. We have mostly focused, in particular, on its practical implementation to 625 identify individuals infected with a virus whose RNA is detected with the test. The 626 strategy is characterized by the number of stages, k + 1, and the sequence of pool sizes, 627 m = (m 1 , ..., m k ), that satisfy m j /m j+1 ∈ N >1 for 1 ≤ j ≤ k and m k+1 = 1. We have 628 analytic expressions for its cost (the expected number of tests per individual) and 629 optimal parameters (k and m that minimize the cost) as functions of the infection 630 probability, p (S1 Appendix, Sec. 1). As proved in [14] , it only makes sense to apply it if 631 p satisfies Eq. (1). The cost scales as p log(1/p), implying a similar reduction as other 632 December 31, 2020 23/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 4, 2021. ; strategies [13, 18] , some of which have the disadvantage, for practical implementations, 633 of requiring a number of stages that is unknown a priori. Given that the optimal within 634 our approach is determined analytically, the time it will take for it to resolve the 635 number of infected individuals within a certain population can be estimated from the 636 very beginning. The analyses of the present paper have shown that it is advisable to 637 use, whenever possible, a strategy with m = (3 k , ..., 3) and k given by Eq. (4) (µ = 3) 638 (Fig. 2) , even if there are some small p intervals for which the optimal strategy is of the 639 form, m = (4 3 k−1 , ..., 3).

In the present paper we have first analyzed the variability of the number of tests of 641 the strategy around its expected value, which determines the cost studied in [14] . We 642 found that the relatively large standard deviation is mostly due to the large number of 643 pools that initially turn out to be negative. Thus, we can expect that fluctuations about 644 the mean will more likely result in fewer tests per individual than the cost. We have 645 then studied the impact of restrictions for the use of the strategy of the form, 646 m = (3 k , ..., 3), that is optimal for the given infection probability, p. In particular, we 647 have analyzed how to proceed when p is unknown a priori or when the optimal starting 648 pool size is larger than the maximum allowed by the test for a reliable detection of the 649 RNA of interest. We have shown that, if the number of stages, k + 1, is small enough, 650 noticeable reductions in the cost are obtained even if the strategy is not optimal for the 651 infection probability of the analyzed population ( Fig. 5 (a) ). We have also discussed 652 how to estimate p before or during the application of the strategy (S1 Appendix, Sec. 2). 653 Given an upper bound on the maximum pool size, depending on p, strategies that start 654 with m 1 = 3 k could eventually reduce the cost more than those of the form, 655 m = (3 k , ..., 3) (Fig. 5 (b) ). In such a case the sequence of pool sizes, m, can be chosen 656 algorithmically as explained in S1 Appendix, Sec. 1. The use of the strategies with 657 m = (3 k , ..., 3) have other advantages that we observed when applying our method in 658 parallel on many pools at the same time as would be done when using multi-well plates 659 to run the PCR test. In particular, the ratio between the expected number of tests at 660 any given stage of the strategy and the number performed at the first stage increases 661 with the ratio of subsequent pool sizes (Fig. 7) . This means that, if we perform the first 662 stage test on N w pools simultaneously (N w is, e.g., the number of wells of the plate), at 663 subsequent stages we will need more than N w wells to accommodate the pools that 664 come from those that tested positive at the first stage and that the number of 665 additional wells will be larger, the larger the fraction between successive pool sizes of 666 the strategy. Reducing this overflow of tests is good for bookkeeping purposes. The 667 m = (3 k , ..., 3) strategies present an appealing good balance between cost reduction even 668 under non-optimal conditions and relatively small overflows (Tables 1 and 2) .

The use of pool testing for the detection of viral RNA allows a widespread 670 surveillance of the population that might be infected keeping costs under control at the 671 same time. However, it carries two main problems. One is related to detectability: what 672 is the maximum number of samples that can be mixed together so that the viral RNA 673 content coming from even a single infected sample can be detected? The other one is 674 related to detecting flawed samples. When samples are tested individually, the quality is 675 assured by detecting a specific human RNA that is co-extrated with the viral genome. 676 In the absence of this detection, the result of the test is not informed. In this paper we 677 have analyzed this problem assuming that ddPCR not only has a greater sensitivity 678 with respect to RTqPCR for viral RNA detection, but it also allows for the direct 679 quantification of the nucleic acid content in a large dynamic range (S1 Appendix, Sec. 680 3). Given that the present work was originally motivated by the current COVID-19 681 pandemic, we contrasted some of our results with data obtained from people infected 682 with SARS-CoV-2. We have shown that, assuming that ddPCR allows the detection of 683 December 31, 2020 24/28 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 4, 2021. ; a single RNA molecule in the tested volume, even the samples of lowest viral load 684 reported in [34] could be detected in 3-sample pools in over 95% of the cases (Fig. 8 ).

Samples with average viral RNA content, on the other hand, could be detected, 686 according to our calculations, in pools of 27 samples or more. The problem associated 687 to sensitivity loss due to pooling can be partially resolved if the samples are tested more 688 than once. Our strategy does so with those that belong to pools that test positive at 689 the first stage, which gives reassurance to those results. In this regard, the nested 690 nature of our strategy is advantageous, especially along with the quantification of the 691 RNA content. We have shown, in particular, how the quantification achieved at the 692 various stages of the strategy could be used for self-consistency checks or to quantify the 693 viral RNA content in samples with very high load for which the individual testing could 694 not give such an estimate.

Regarding the detectability of unviable samples with inhibitors or degraded RNA 696 (invalid samples) in pool testing, we analyzed the possibility of discerning between pools 697 with m valid samples samples and pools with one invalid and m − 1 viable specimens. 698 Assuming that the variability of the human RNA content among individuals was 699 described by a Normal distribution, we found ranges of concentrations for which such 700 discrimination was possible with more than 99% accuracy for m = 3 and m = 9 and 701 with more than 95% accuracy for m = 27. The current standard is to use human RNase 702 P RNA. Whether the corresponding RNA content can lie within the dynamic ranges 703 established by our calculations in the testing volume needs further studies. In any case, 704 if the analysis turns out to be positive, at least, for certain pool sizes, together with the 705 nested nature of our strategy that allows to infer information on previous stages from . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 4, 2021. ; https://doi.org/10.1101/2021.01.03.21249170 doi: medRxiv preprint

COVID-19 diagnostics in context

Group Testing for Identification

Group Testing for Estimation

The Detection of Defective Members of Large Populations

On the Detection of Defective Members of Large Populations

Group testing to eliminate efficiently all defectives in a binomial sample

A Method for Detecting All Defective Members in a Population by Group Testing

Rates of Adaptive Group Testing in the Linear Regime

Group Testing: An Information Theory Perspective. Foundations and Trends in Communications and Information Theory Series

The use of a square array scheme in blood testing

Comparison of Group Testing Algorithms for Case Identification in the Presence of Test Error

Two-Dimensional Informative Array Testing

Group testing with random pools: optimal two-stage algorithms

Group testing with nested pools

Boosting test-efficiency by pooled testing strategies for SARS-CoV-2

Analysis and Applications of Non-Adaptive and Adaptive Group Testing Methods for COVID-19

Evaluation of Group Testing for SARS-CoV-2 RNA. medRxiv

A pooled testing strategy for identifying SARS-CoV-2 at low prevalence

The mathematical strategy that could transform coronavirus testing

Large-scale implementation of pooled RNA extraction and RT-PCR for SARS-CoV-2 detection

Efficient high throughput SARS-CoV-2 testing to detect asymptomatic carriers

Lessons from applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests

ddPCR: a more accurate tool for SARS-CoV-2 detection in low viral load specimens

Group Testing for Severe Acute Respiratory Syndrome-Coronavirus 2 to Enable Rapid Scale-up of Testing and Real-Time Surveillance of Incidence

Analytical comparisons of SARS-COV-2 detection by qRT-PCR and ddPCR with multiple primer/probe sets

Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients

ddPCR: a more sensitive and accurate tool for SARS-CoV-2 detection in low viral load specimens

LAMP-Seq: Population-Scale COVID-19 Diagnostics Using Combinatorial Barcoding

Considerations for diagnostic COVID-19 tests

Evaluation of COVID-19 RT-qPCR test in multi-sample pools

Sensitivity assessment of droplet digital PCR for SARS-CoV-2 detection

High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number

Absolute quantification by droplet digital PCR versus analog real-time PCR

Quantitative Detection and Viral Load Analysis of SARS-CoV-2 in Infected Patients

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Viral load of SARS-CoV-2 in clinical samples. The Lancet Infectious Diseases

We would like to thank Pablo Aguilar, Alejandro Colaneri and Juliana Sesma for useful 728 discussions and suggestions. This work was partially supported by UBA (UBACyT 729